Mark Erlander is the founder of Cardiff Oncology. Cardiff Oncology has raised $200M in total funding. Latest round: Growth.
Mark Erlander, Ph.D., is a biotech CEO specializing in oncology therapeutics. He formerly served as Chief Executive Officer of Cardiff Oncology, where he led the company through its name change and oversaw the advancement of its lead drug, onvansertib, through Phase 2 trials.
Full founder directory · Investor directory · Company funding database · Fundraising library